vs
碧迪（BDX）与开利（CARR）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是开利的1.1倍（$5.3B vs $4.8B），碧迪净利率更高（7.3% vs 1.1%，领先6.2%），开利同比增速更快（33.2% vs -0.4%），开利自由现金流更多（$909.0M vs $549.0M），过去两年碧迪的营收复合增速更高（2.0% vs -11.5%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
开利全球是总部位于美国佛罗里达州棕榈滩花园的跨国企业，成立于1915年，主营暖通空调、制冷、消防及安防设备。公司最初以生产销售暖通空调系统起家，后续逐步拓展业务，覆盖商用制冷、餐饮服务设备及消防安防技术等领域。
BDX vs CARR — 直观对比
营收规模更大
BDX
是对方的1.1倍
$4.8B
营收增速更快
CARR
高出33.6%
-0.4%
净利率更高
BDX
高出6.2%
1.1%
自由现金流更多
CARR
多$360.0M
$549.0M
两年增速更快
BDX
近两年复合增速
-11.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $4.8B |
| 净利润 | $382.0M | $53.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 2.1% |
| 净利率 | 7.3% | 1.1% |
| 营收同比 | -0.4% | 33.2% |
| 净利润同比 | 24.0% | -97.9% |
| 每股收益（稀释后） | $1.34 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXCARR
| Q4 25 | $5.3B | $4.8B | ||
| Q3 25 | $5.9B | $5.6B | ||
| Q2 25 | $5.5B | $6.1B | ||
| Q1 25 | $5.3B | $5.2B | ||
| Q4 24 | $5.2B | $3.6B | ||
| Q3 24 | $5.4B | $6.0B | ||
| Q2 24 | $5.0B | $6.7B | ||
| Q1 24 | $5.0B | $6.2B |
净利润BDXCARR
| Q4 25 | $382.0M | $53.0M | ||
| Q3 25 | $493.0M | $428.0M | ||
| Q2 25 | $574.0M | $591.0M | ||
| Q1 25 | $308.0M | $412.0M | ||
| Q4 24 | $303.0M | $2.6B | ||
| Q3 24 | $400.0M | $447.0M | ||
| Q2 24 | $487.0M | $2.3B | ||
| Q1 24 | $537.0M | $269.0M |
毛利率BDXCARR
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXCARR
| Q4 25 | 10.5% | 2.1% | ||
| Q3 25 | 11.8% | 9.7% | ||
| Q2 25 | 16.0% | 14.8% | ||
| Q1 25 | 10.4% | 12.1% | ||
| Q4 24 | 8.8% | -63.6% | ||
| Q3 24 | 11.4% | 12.8% | ||
| Q2 24 | 12.1% | 55.2% | ||
| Q1 24 | 14.5% | 8.1% |
净利率BDXCARR
| Q4 25 | 7.3% | 1.1% | ||
| Q3 25 | 8.4% | 7.7% | ||
| Q2 25 | 10.4% | 9.7% | ||
| Q1 25 | 5.8% | 7.9% | ||
| Q4 24 | 5.9% | 70.3% | ||
| Q3 24 | 7.4% | 7.5% | ||
| Q2 24 | 9.8% | 34.9% | ||
| Q1 24 | 10.6% | 4.4% |
每股收益（稀释后）BDXCARR
| Q4 25 | $1.34 | $0.07 | ||
| Q3 25 | $1.71 | $0.50 | ||
| Q2 25 | $2.00 | $0.68 | ||
| Q1 25 | $1.07 | $0.47 | ||
| Q4 24 | $1.04 | $2.82 | ||
| Q3 24 | $1.37 | $0.49 | ||
| Q2 24 | $1.68 | $2.55 | ||
| Q1 24 | $1.85 | $0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.6B |
| 总债务越低越好 | — | $11.4B |
| 股东权益账面价值 | $25.3B | $14.1B |
| 总资产 | $54.8B | $37.2B |
| 负债/权益比越低杠杆越低 | — | 0.80× |
8季度趋势，按日历期对齐
现金及短期投资BDXCARR
| Q4 25 | $740.0M | $1.6B | ||
| Q3 25 | $641.0M | $1.4B | ||
| Q2 25 | $735.0M | $1.8B | ||
| Q1 25 | $667.0M | $1.7B | ||
| Q4 24 | $711.0M | $4.0B | ||
| Q3 24 | $1.7B | $2.2B | ||
| Q2 24 | $4.5B | $2.9B | ||
| Q1 24 | $2.3B | $1.3B |
总债务BDXCARR
| Q4 25 | — | $11.4B | ||
| Q3 25 | — | $11.3B | ||
| Q2 25 | — | $11.3B | ||
| Q1 25 | — | $11.1B | ||
| Q4 24 | — | $11.0B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | — | $11.3B | ||
| Q1 24 | — | $15.6B |
股东权益BDXCARR
| Q4 25 | $25.3B | $14.1B | ||
| Q3 25 | $25.4B | $14.8B | ||
| Q2 25 | $25.5B | $15.0B | ||
| Q1 25 | $25.2B | $14.2B | ||
| Q4 24 | $25.2B | $14.4B | ||
| Q3 24 | $25.9B | $15.0B | ||
| Q2 24 | $25.9B | $14.1B | ||
| Q1 24 | $25.6B | $11.9B |
总资产BDXCARR
| Q4 25 | $54.8B | $37.2B | ||
| Q3 25 | $55.3B | $38.1B | ||
| Q2 25 | $54.9B | $38.5B | ||
| Q1 25 | $54.5B | $36.4B | ||
| Q4 24 | $54.7B | $37.4B | ||
| Q3 24 | $57.3B | $40.2B | ||
| Q2 24 | $55.6B | $40.4B | ||
| Q1 24 | $54.2B | $40.8B |
负债/权益比BDXCARR
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 0.69× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 1.31× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.0B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $909.0M |
| 自由现金流率自由现金流/营收 | 10.5% | 18.8% |
| 资本支出强度资本支出/营收 | 2.1% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.72× | 19.62× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $2.1B |
8季度趋势，按日历期对齐
经营现金流BDXCARR
| Q4 25 | $657.0M | $1.0B | ||
| Q3 25 | $1.4B | $341.0M | ||
| Q2 25 | $1.2B | $649.0M | ||
| Q1 25 | $164.0M | $483.0M | ||
| Q4 24 | $693.0M | $132.0M | ||
| Q3 24 | $1.2B | $-269.0M | ||
| Q2 24 | $1.3B | $660.0M | ||
| Q1 24 | $514.0M | $40.0M |
自由现金流BDXCARR
| Q4 25 | $549.0M | $909.0M | ||
| Q3 25 | $1.0B | $224.0M | ||
| Q2 25 | $1.0B | $568.0M | ||
| Q1 25 | $35.0M | $420.0M | ||
| Q4 24 | $588.0M | $-85.0M | ||
| Q3 24 | $882.0M | $-356.0M | ||
| Q2 24 | $1.1B | $549.0M | ||
| Q1 24 | $380.0M | $-64.0M |
自由现金流率BDXCARR
| Q4 25 | 10.5% | 18.8% | ||
| Q3 25 | 17.0% | 4.0% | ||
| Q2 25 | 19.0% | 9.3% | ||
| Q1 25 | 0.7% | 8.0% | ||
| Q4 24 | 11.4% | -2.3% | ||
| Q3 24 | 16.2% | -5.9% | ||
| Q2 24 | 22.4% | 8.2% | ||
| Q1 24 | 7.5% | -1.0% |
资本支出强度BDXCARR
| Q4 25 | 2.1% | 2.7% | ||
| Q3 25 | 6.0% | 2.1% | ||
| Q2 25 | 3.2% | 1.3% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 2.0% | 6.0% | ||
| Q3 24 | 5.4% | 1.5% | ||
| Q2 24 | 3.6% | 1.7% | ||
| Q1 24 | 2.7% | 1.7% |
现金转化率BDXCARR
| Q4 25 | 1.72× | 19.62× | ||
| Q3 25 | 2.75× | 0.80× | ||
| Q2 25 | 2.12× | 1.10× | ||
| Q1 25 | 0.53× | 1.17× | ||
| Q4 24 | 2.29× | 0.05× | ||
| Q3 24 | 2.94× | -0.60× | ||
| Q2 24 | 2.66× | 0.28× | ||
| Q1 24 | 0.96× | 0.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
CARR
| Products | $4.1B | 86% |
| Services | $699.0M | 14% |
